

# Relation of Electrocardiographic Left Atrial Abnormalities to Risk of Stroke in Patients with Atrial Fibrillation



Yuko Y. Inoue, MD, PhD<sup>a,b</sup>, Esra G. Ipek, MD<sup>a</sup>, Irfan M. Khurram, MD<sup>a,c</sup>, Luisa Ciuffo, MD<sup>a</sup>, Jonathan Chrispin, MD<sup>a</sup>, Stefan L. Zimmerman, MD<sup>d</sup>, Joseph E. Marine, MD<sup>a</sup>, John Rickard, MD<sup>e</sup>, David D. Spragg, MD<sup>a</sup>, Saman Nazarian, MD, PhD<sup>f</sup>, Kengo Kusano, MD, PhD<sup>b</sup>, Joao A. Lima, MD<sup>a,d,g</sup>, Ronald D. Berger, MD, PhD<sup>a,h</sup>, Hugh Calkins, MD<sup>a</sup>, and Hiroshi Ashikaga, MD, PhD<sup>a,\*</sup>

**The P-wave terminal force in lead V<sub>1</sub> (PTFV<sub>1</sub>) on the 12-lead electrocardiogram (ECG) quantifies left atrial (LA) structural and electrophysiologic abnormalities. We aimed to evaluate the association between PTFV<sub>1</sub> and cerebrovascular accident (CVA) as well as LA structure and function in patients with atrial fibrillation (AF). We conducted a cross-sectional study of 229 patients with AF (60 ± 10 years, 72% men) with (n = 21) and without (n = 208) a history of CVA, who underwent preablation ECG and cardiac magnetic resonance in sinus rhythm. PTFV<sub>1</sub> was defined as the duration (in milliseconds) of the downward deflection of the P wave in lead V<sub>1</sub> multiplied by the absolute value of its amplitude (in microvolts) on ECG. PTFV<sub>1</sub> is associated with LA minimum volume (V<sub>min</sub>) and left ventricular ejection fraction but not associated with the extent of LA fibrosis quantified by cardiac magnetic resonance late gadolinium enhancement. In addition, PTFV<sub>1</sub> is associated with CVA independent of the CHA<sub>2</sub>DS<sub>2</sub>-VASc score and LA V<sub>min</sub> (odds ratio 1.23; 95% confidence interval 1.08 to 1.40; p = 0.002). Furthermore, PTFV<sub>1</sub> has an incremental value over the CHA<sub>2</sub>DS<sub>2</sub>-VASc score as a marker of CVA (p < 0.001). In conclusion, ECG-defined PTFV<sub>1</sub> is independent marker of stroke in patients with AF and reflects the underlying LA remodeling. Our findings suggest that evaluation of PTFV<sub>1</sub> can improve the current risk stratification of stroke. © 2018 Elsevier Inc. All rights reserved. (Am J Cardiol 2018;122:242–247)**

Atrial fibrillation (AF) is associated with a fivefold increased risk of thromboembolism.<sup>1</sup> The current approach

<sup>a</sup>Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, Maryland; <sup>b</sup>Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan; <sup>c</sup>Division of Cardiology, New York Presbyterian/Columbia University Medical Center, New York, New York; <sup>d</sup>The Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland; <sup>e</sup>Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio; <sup>f</sup>Section for Cardiac Electrophysiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; <sup>g</sup>Department of Epidemiology, Johns Hopkins University School of Public Health, Baltimore, Maryland; and <sup>h</sup>Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland. Manuscript received December 2, 2017; revised manuscript received and accepted March 27, 2018.

This work was supported by research grants from Philips Healthcare (to H.A.), the W.W. Smith Charitable Trust (to H.A.), the Magic That Matters Fund for Cardiovascular Research (to H.A.), the Zegar Family Foundation (to H.A.), the Johns Hopkins University Institute of Clinical and Translational Research (to H.A.), the Japan Cardiovascular Research Foundation (to Y.I.), SHISEIKAI Scientific Award (to Y.I.), Daiwa Securities Health Foundation (to Y.I.), a Boston Scientific Corporation Fellowship Grant (to R.B.), the Edward St. John Foundation for AF Research (to H.C.), The Roz and Marvin H Weiner and Family Foundation (to H.C.), The Dr. Francis P. Chiaramonte Foundation (to H.C.), The Marilyn and Christian Poindexter Arrhythmia Research Fund (to H.C.), and the Norbert and Louise Grunwald Cardiac Arrhythmia Research Fund (to H.C.).

See page 246 for disclosure information.

\*Corresponding author: Tel: 410-502-7861; fax: 410-502-0231.

E-mail address: [hashika1@jhmi.edu](mailto:hashika1@jhmi.edu) (H. Ashikaga).

to estimate the risk of stroke in patients with AF is the CHA<sub>2</sub>DS<sub>2</sub>-VASc scoring system, and oral anticoagulation is recommended for the patients with a score of 2 or greater. Although the CHA<sub>2</sub>DS<sub>2</sub>-VASc scoring system is an extremely simple and cost-effective method to estimate the risk of stroke, there is a clinical need for an improved method that provides an incremental value over the CHA<sub>2</sub>DS<sub>2</sub>-VASc score by quantifying the underlying left atrial (LA) remodeling associated with AF, and yet is equivalently simple and cost-effective. The P-wave terminal force in lead V<sub>1</sub> (PTFV<sub>1</sub>) on the standard 12-lead electrocardiogram (ECG) is a simple parameter to quantify structural<sup>2,3</sup> and electrophysiologic abnormalities of the left atrium.<sup>4</sup> In this study, we aimed to evaluate the association between PTFV<sub>1</sub> and LA remodeling such as LA size and fibrosis derived from cardiac magnetic resonance (CMR) in patients with AF. We also aimed to evaluate the association between PTFV<sub>1</sub> and cerebrovascular accident (CVA).

## Methods

We conducted a prospective cross-sectional study of 346 consecutive patients with drug-refractory symptomatic AF referred for CMR imaging for definition of pulmonary vein anatomy before the first-time catheter ablation of AF. Patients with AF at the time of ECG or CMR were excluded (n = 117; Figure 1). The remaining 229 patients who were in sinus rhythm at the time of both ECG and CMR were included in the final analysis. The CVA group (n = 21; 9.2%) was defined as those with a history of ischemic




Figure 1. Patient enrollment. AF = atrial fibrillation; CMR = cardiac magnetic resonance; CVA = cerebrovascular accident; ECG = electrocardiogram; TIA = transient ischemic attack.

stroke or transient ischemic attack (TIA) before ECG or CMR; the remaining patients were designated as the control group ( $n = 208$ ; 90.8%). The thromboembolic risk was assessed by the CHADS<sub>2</sub> and the CHA<sub>2</sub>DS<sub>2</sub>-VASc scores before development of CVA. The Johns Hopkins Institutional Review Board approved the study and all patients provided written informed consent.

The standard 12-lead ECG was recorded at rest by the Marquette MAC 5000 ECG system (GE Medical Systems, Milwaukee, Wisconsin) calibrated at 10 mm/mV with a speed of 25 mm/s. An experienced electrophysiologist, blinded to the group, made P-wave measurements manually from the ECG acquired immediately before CMR. PTFV<sub>1</sub> was defined as the absolute value of the depth (in millivolts) of the downward deflection (terminal portion) of the P wave (P') in ECG lead V<sub>1</sub> multiplied by its duration (in milliseconds) (Figure 2).

CMR was performed using a 1.5-T magnetic resonance imaging scanner (Avanto and Aera, Siemens, Erlangen, Bavaria, Germany) equipped with a phased array cardiac coil. Vertical and horizontal long-axis cine CMR was

performed using a steady-state free precession sequence (minimal repetition time/echo time, flip angle of 80°, an in-plane resolution of  $1.4 \times 1.4$  mm, a slice thickness of 8 mm, and a spacing of 2 mm) with temporal resolution of 20 to 40 ms. We used off-line semiautomated multimodality tissue-tracking software version 6.0 (Toshiba, Tokyo, Japan) to analyze the LA and left ventricular (LV) structure and function in long-axis two- and four-chamber cine images.<sup>5</sup> The LA maximum and minimum volumes ( $V_{\max}$  and  $V_{\min}$ ) were obtained from the phasic volume curve to calculate the following functional parameters: all the LA volumes were indexed by the body surface area. LA emptying fraction (EF) =  $(V_{\max} - V_{\min}) \times 100\% / V_{\max}$ . In 229 patients included in the final analysis, 117 (51%,  $n = 13$  in the CVA group and  $n = 104$  in control group) also underwent late gadolinium enhancement (LGE) to quantify LA fibrosis as described previously.<sup>6</sup>

Continuous variables are presented as mean  $\pm$  SD or median and interquartile range as appropriate. Categorical variables are presented as frequencies and percentages. Differences between group means were evaluated with




Figure 2. Illustration of components of P-wave terminal force in lead V<sub>1</sub> (PTFV<sub>1</sub>). PTFV<sub>1</sub> is defined as the duration (in milliseconds) of the downward deflection (shaded gray area) of the P wave in lead V<sub>1</sub> multiplied by the absolute value of its amplitude (in microvolts).

Download English Version:

<https://daneshyari.com/en/article/8651158>

Download Persian Version:

<https://daneshyari.com/article/8651158>

[Daneshyari.com](https://daneshyari.com)